Brazil Launches EficazControl Biocontrol Agent Yields Up 3.71 Bags per Hectare Approved for Soybean Corn Disease Protection
Brazilian agri-tech firm Simbiose has unveiled EficazControl, the nation’s first biopesticide based on the Paenibacillus ottowii strain, at the ANDAV 2025 conference. The new product is designed to shield major crops—soybeans, corn, and cotton—from devastating soil-borne diseases, offering up to 80% protection against key root and stem rot pathogens.
EficazControl, jointly developed with Embrapa over nine years, also contains Bacillus velezensis and has gained full regulatory approval from Brazil’s agriculture, environment, and health authorities. Field results show it can control Fusarium, Colletotrichum, and Macrophomina, among others.
Significantly, Embrapa’s trials reveal that EficazControl outperforms chemical fungicides as a seed treatment, boosting yields by an extra 3.71 bags per hectare. Unlike chemical fungicides, which require separate registration for each crop, this biopesticide is authorized for all crops affected by the target diseases.
Marcelo de Godoy Oliveira, CEO of Cogny, highlighted the competitive edge EficazControl brings to Simbiose in the lucrative soybean market, where annual fungicide sales top 400 million reais. The product is set for commercial use in the 2025/26 planting season, signaling a new era for sustainable crop protection in Brazil.
2026-10-13
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Dow Swings from an $801 Million Loss to an $802 Million Profit as Hormuz Disruption Lifts Polyethylene Prices
-
Türkiye Advances $3 Billion Petrochemical Cluster Targeting 17% of Domestic Polypropylene Demand
-
Argentina to Build Latin America’s Largest Urea Plant Under €1.3 Billion Contract
-
April Chemical Industry Shutdown Wave Arrives: Maintenance Plans Reflect Deep Cost Anxiety Across Enterprises
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
A $25 Billion “Mega Merger” Is Born: How the AkzoNobel × Axalta Deal Rewrites Global Coatings Power
Recommend Reading
-
Fracturing the Crown: BASF Antwerp’s 600-Job Cut and the Global Alarm
-
Dafeng Haijianuo’s RMB 246 Million Technical Revamp Project Takes Shape, with Multiple Production Lines for Vitamin K1, Folic Acid, and Others Under Construction
-
Procter & Gamble Posts Higher Profits on Strong Personal Care Sales and Recovery in China
-
BASF Approves €1 Billion Share Buyback Program as Chemical Giant Prioritizes Capital Discipline
-
Behind Starbucks China’s Ownership Change: The Race for Localization and Efficiency
-
Applications of Copper Sulfate Pentahydrate
-
Supply-side factors push up formic acid prices, but insufficient demand halts the upward trend
-
Business Society October 13, 2026 Isooctanol Trend Analysis: Uptrend Confirmed
-
Business Society October 12, 2026 Epoxy Chloropropane Trend Analysis: Volatility (Strong Consolidation, Bullish Bias)
-
Acetic Acid Market Continues to Decline in China